EWM
NTLA icon

Elmwood Wealth Management’s Intellia Therapeutics NTLA Stock Holding History

Elmwood Wealth Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.74M Buy
102,944
+20
+0% +$280 0.44% 59
2026
Q1 		$1.32M Buy
102,924
+25,000
+32% +$318K 0.36% 68
2025
Q4 		$701K Sell
77,924
-135
-0.2% -$1.86K 0.22% 99
2025
Q3 		$1.35M Buy
78,059
+10,135
+15% +$125K 0.48% 61
2025
Q2 		$637K Buy
67,924
+135
+0.2% +$1.11K 0.25% 87
2025
Q1 		$482K Buy
67,789
+15
+0% +$152 0.2% 97
2024
Q4 		$790K Hold
67,774
– – 0.32% 83
2024
Q3 		$1.39M Buy
67,774
+600
+0.9% +$13.8K 0.57% 62
2024
Q2 		$1.5M Sell
67,174
-725
-1% -$17.3K 0.67% 57
2024
Q1 		$1.87M Sell
67,899
-10
-0% -$278 0.8% 48
2023
Q4 		$2.07M Buy
67,909
+10
+0% +$287 1.45% 19
2023
Q3 		$2.15M Hold
67,899
– – 1.04% 31
2023
Q2 		$2.77M Hold
67,899
– – 1.29% 24
2023
Q1 		$2.53M Hold
67,899
– – 1.2% 27
2022
Q4 		$2.37M Hold
67,899
– – 1.18% 24
2022
Q3 		$3.8M Hold
67,899
– – 1.9% 8
2022
Q2 		$3.51M Buy
67,899
+300
+0.4% +$15.2K 2% 11
2022
Q1 		$4.91M Buy
67,599
+425
+0.6% +$36K 2.52% 5
2021
Q4 		$7.94M Buy
+67,174
New +$8.42M 3.79% 2
2021
Q2 		$10.9M Hold
67,174
– – 5.73% 1
2021
Q1 		$5.39M Buy
+67,174
New +$4.51M 3.29% 4
2020
Q3 		$1.35M Hold
64,204
– – 1.09% 28
2020
Q2 		$1.35M Buy
64,204
+15,066
+31% +$256K 1.09% 28
2020
Q1 		$1.04M Sell
49,138
-15,066
-23% -$203K 0.99% 37
2019
Q4 		$942K Sell
64,204
-65,235
-50% -$908K 0.82% 53
2019
Q3 		$1.73M Sell
129,439
-3,705
-3% -$59.1K 1.75% 15
2019
Q2 		$2.18M Sell
133,144
-3,705
-3% -$58.2K 1.93% 7
2019
Q1 		$2.34M Buy
136,849
+75,227
+122% +$1.12M 2.16% 5
2018
Q4 		$841K Sell
61,622
-3,705
-6% -$68.9K 0.81% 45
2018
Q3 		$1.87M Buy
65,327
+4,985
+8% +$145K 1.55% 17
2018
Q2 		$1.65M Buy
60,342
+11,204
+23% +$271K 1.5% 19
2018
Q1 		$1.04M Buy
+49,138
New +$1.21M 0.99% 37

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Elmwood Wealth Management's NTLA Position: Q2 2026 in Review

Elmwood Wealth Management increased its Intellia Therapeutics (NTLA) stake by 0.02% in Q2 2026, buying an estimated $280 and bringing the position to 102,944 shares worth $1.74M. The position accounts for 0.44% of the portfolio, ranked #59.

Elmwood Wealth Management first reported a position in NTLA in Q1 2018 and has held it in 32 quarters since. The position peaked at $10.9M in Q2 2021. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Elmwood Wealth Management held 102,944 shares of Intellia Therapeutics worth $1.74M as of Q2 2026.
  • Elmwood Wealth Management bought 20 Intellia Therapeutics shares in Q2 2026, an estimated $280.
  • Intellia Therapeutics made up 0.44% of Elmwood Wealth Management's portfolio in Q2 2026, its #59 holding.
  • Elmwood Wealth Management first reported a position in Intellia Therapeutics in Q1 2018 and has held it in 32 quarters since.
  • Elmwood Wealth Management's Intellia Therapeutics position peaked at $10.9M in Q2 2021.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Elmwood Wealth Management's 13F filing for Q2 2026, filed 8 Jul 2026.